Aitiologic, a Vienna-based precision medicine company, announced on 15 September 2026 that it had raised €6.4m (about $7.4m) in an oversubscribed seed round.
Heal Capital and Ananda Impact Ventures co-led the round, with existing investors PUSH VC and LANA Ventures taking part. Gordon Sanghera, co-founder and former chief executive of Oxford Nanopore Technologies, also invested and joined the company's advisory board. No valuation was disclosed.
The company said the money would advance its Aitios platform and its lead programme, a first-trimester test for the risk of preeclampsia, a pregnancy complication and a leading cause of preventable maternal deaths.
“Preeclampsia is a compelling first application because the unmet need for early risk prediction is significant and the clinical care pathway already exists. Longer-term, our ambition is much broader: to transform a routine blood draw into a rich source of molecular information about maternal and fetal health, and ultimately to make tissue-specific biology accessible from blood across a much wider range of conditions.”Dr. Andreas E. Posch, CEO and Founder, Aitiologic
What Aitiologic does
Aitios is a liquid biopsy platform that analyses cell-free DNA in the blood. It combines several types of cell-free DNA data with AI to identify which tissue DNA fragments came from and to pick up tissue-specific biological changes from a blood sample.
The platform relies on patented methods that founder and chief executive Andreas E. Posch helped develop at Siemens Healthineers, to which Aitiologic holds an exclusive licence, according to Trending Topics. The company was founded in 2023.
Trending Topics named Stephan Beisken and Achim Plum as part of the founding team alongside Posch. Posch told the publication the company had moved from a technology hypothesis to published clinical data: Aitiologic presented feasibility results to more than 1,500 clinicians and researchers at the Fetal Medicine Foundation conference in London in December 2025, and a paper on first-trimester cell-free DNA analysis for preeclampsia appeared in AJOG Global Reports in June 2026, according to the company's website.
For its first product, Aitiologic uses the blood sample already taken for non-invasive prenatal testing, so pregnant women would need no additional blood draw. Posch said preeclampsia was a strong first application because the need for early risk prediction is large and a clinical care pathway already exists.
What the money is for
Aitiologic is running a validation study of more than 1,000 pregnancies with the Fetal Medicine Foundation. It builds on an earlier feasibility study with Professor Kypros Nicolaides and the Fetal Medicine Research Institute, which found the method could stratify the risk of preterm and term preeclampsia from a first-trimester blood sample, Trending Topics reported.
Dealroom said the funds would go to large-scale validation and regulated product development. If validation succeeds, the company plans to take the platform beyond preeclampsia, FemTech Insider reported. Posch said the longer-term aim was to make tissue-specific biology accessible from blood across a much wider range of conditions.
Coverage of the round also highlighted Rebecca Ertl, an obstetrician-gynaecologist, as chief medical officer. The company's website shows she presented the feasibility results in London in her CMO role in December 2025.
Who invested
Heal Capital is a German life sciences and healthcare fund, and this was its first investment in Austria, according to law firm CMS, which advised it on the deal. Christian Lautner, a managing partner at Heal Capital, said the team combined "scientific excellence with a clear focus on clinical application".
Brandl & Talos advised Aitiologic and PÖLLATH advised Ananda Impact Ventures, CMS said. Dealroom reported that the round ranks among the largest seed deals in Austria's health sector.
The company did not disclose earlier funding amounts or a headcount.
Company website: aitiologic.com